A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder

Simply Wall St.01-15

Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603628910?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-15 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603628910","market":"sg","top_or_hot":-1,"title":"A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder","media":"Simply Wall St.","content":"<div>\n<p>Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 02:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl","article_id":"2603628910","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603628910","pubTimestamp":1768416671,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in a large patient population.\nSee our latest analysis for Luye Pharma Group.\nThe NDA news has arrived after a mixed period for Luye Pharma Group. The 30 day share price return is 5.99%, while the 90 day share price return shows a 16.16% decline. The 1 year total shareholder return of 49.75%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","BK1191":"制药","BK1583":"高瓴概念","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02186":"绿叶制药"},"translate_title":"若新林焦虑症NDA获批后绿叶制药集团（SEHK：2186）估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02186":0.9},"content_text":"Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in a large patient population. See our latest analysis for Luye Pharma Group. The NDA news has arrived after a mixed period for Luye Pharma Group. The 30 day share price return is 5.99%, while the 90 day share price return shows a 16.16% decline. The 1 year total shareholder return of 49.75% contrasts with weaker 3 and 5 year total shareholder returns, suggesting that short term momentum has picked up even as longer term holders have experienced a tougher run. If this kind of drug pipeline progress has your attention, it could be a good moment to scan healthcare stocks for other healthcare names catching investors’ interest. With Luye Pharma Group trading at HK$3.01, sitting at a discount to analyst price targets and with mixed multi year returns, should you view this as undervalued CNS potential, or as a stock that already reflects expectations for future growth in its current price? AdvertisementPrice to Earnings of 27.1x: Is it justified? Luye Pharma Group is trading on a P/E of 27.1x at a last close of HK$3.01, which sits between a cheaper peer average and a richer sector benchmark. The P/E ratio compares the share price with earnings per share, so for a company like Luye Pharma Group it effectively tells you how much investors are paying for each unit of current profit. On one hand, the shares are described as good value against a peer average P/E of 29.8x, which suggests earnings are not being priced at a premium within that peer set. On the other hand, the same 27.1x P/E is called expensive versus both the broader Hong Kong Pharmaceuticals industry average of 13.4x and an estimated fair P/E of 22.7x, implying the market price could move closer to that lower fair ratio if sentiment or expectations cool. Explore the SWS fair ratio for Luye Pharma Group Result: Price-to-Earnings of 27.1x (OVERVALUED) However, the mixed 3 and 5 year total returns and a P/E above the broader industry level leave the share price exposed if drug data or regulatory timelines disappoint. Find out about the key risks to this Luye Pharma Group narrative. Another View: What Does The SWS DCF Model Say? While the 27.1x P/E paints Luye Pharma Group as expensive against the Hong Kong Pharmaceuticals industry, our DCF model points the other way. With the shares at HK$3.01 versus an estimated fair value of HK$13.45, the model suggests a very large discount. Is that a genuine opportunity, or is the DCF too optimistic about the future cash flows? Look into how the SWS DCF model arrives at its fair value. 2186 Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Luye Pharma Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 883 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Luye Pharma Group Narrative If you do not see the story the same way, or you prefer to weigh the numbers yourself, you can test your own view in minutes with Do it your way. A great starting point for your Luye Pharma Group research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If Luye Pharma has sparked new questions for you, it is worth broadening your watchlist so you can compare opportunities and spot patterns across different themes.  Zero in on potential bargains by checking out these 883 undervalued stocks based on cash flows that may offer more earnings for every dollar you commit. Ride the next wave of automation and data crunching by scanning these 25 AI penny stocks that tap into real world adoption of artificial intelligence. Target income focused opportunities by reviewing these 13 dividend stocks with yields > 3% that can add a regular cash return element to your portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603628910","isCrawlerRequest":true}